395 related articles for article (PubMed ID: 30243889)
1. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Layton AJ
Clin Lung Cancer; 2019 Jan; 20(1):20-29.e8. PubMed ID: 30243889
[TBL] [Abstract][Full Text] [Related]
2. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
Faber E; Grosu H; Sabir S; San Lucas FA; Barkoh BA; Bassett RL; Luthra R; Stewart J; Roy-Chowdhuri S
J Clin Pathol; 2022 Sep; 75(9):612-619. PubMed ID: 33952592
[TBL] [Abstract][Full Text] [Related]
3. Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
Sakata S; Otsubo K; Yoshida H; Ito K; Nakamura A; Teraoka S; Matsumoto N; Shiraishi Y; Haratani K; Tamiya M; Ikeda S; Miura S; Tanizaki J; Omori S; Yoshioka H; Hata A; Yamamoto N; Nakagawa K
Cancer Sci; 2022 Jan; 113(1):221-228. PubMed ID: 34704312
[TBL] [Abstract][Full Text] [Related]
4. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.
Lozano MD; Labiano T; Echeveste J; Gurpide A; Martín-Algarra S; Zhang G; Sharma A; Palma JF
Cancer Cytopathol; 2015 Apr; 123(4):230-6. PubMed ID: 25529460
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutation in non-small cell lung cancer.
Sakaguchi T; Iketani A; Furuhashi K; Nakamura Y; Suzuki Y; Ito K; Fujiwara K; Nishii Y; Katsuta K; Taguchi O; Hataji O
Thorac Cancer; 2021 Feb; 12(4):462-467. PubMed ID: 33314600
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice.
Ariyasu R; Uchibori K; Ninomiya H; Ogusu S; Tsugitomi R; Manabe R; Sakamaoto H; Tozuka T; Yoshida H; Amino Y; Kitazono S; Yanagitani N; Takeuchi K; Nishio M
Thorac Cancer; 2021 Feb; 12(4):504-511. PubMed ID: 33350072
[TBL] [Abstract][Full Text] [Related]
7. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.
Robert NJ; Espirito JL; Chen L; Nwokeji E; Karhade M; Evangelist M; Spira A; Neubauer M; Bullock S; Walberg J; Cheng SK; Coleman RL
Lung Cancer; 2022 Apr; 166():197-204. PubMed ID: 35313244
[TBL] [Abstract][Full Text] [Related]
8. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
[TBL] [Abstract][Full Text] [Related]
10. Cytology samples and molecular biomarker testing in lung cancer-advantages and challenges.
Canberk S; Engels M
Virchows Arch; 2021 Jan; 478(1):45-57. PubMed ID: 33389149
[TBL] [Abstract][Full Text] [Related]
11. Adequacy of cytology and small biopsy samples obtained with rapid onsite evaluation (ROSE) for predictive biomarker testing in non-small cell lung cancer.
Hendry S; Mamotte L; Mesbah Ardakani N; Leslie C; Tesfai Y; Grieu-Iacopetta F; Izaac K; Singh S; Ardakani R; Thomas M; Giardina T; Robinson C; Frost F; Amanuel B
Pathology; 2023 Dec; 55(7):917-921. PubMed ID: 37805343
[TBL] [Abstract][Full Text] [Related]
12. Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
Zugazagoitia J; Rueda D; Carrizo N; Enguita AB; Gómez-Sánchez D; Díaz-Serrano A; Jiménez E; Mérida A; Calero R; Lujan R; De Miguel E; Gámez P; Díaz-Hellín V; Nuñez JA; Iglesias L; Ferrer I; Paz-Ares L; Ponce-Aix S
Clin Lung Cancer; 2018 Jan; 19(1):65-73.e7. PubMed ID: 28780976
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients - A single centre experience.
Dall'Olio FG; Conci N; Rossi G; Fiorentino M; De Giglio A; Grilli G; Altimari A; Gruppioni E; Filippini DM; Di Federico A; Nuvola G; Ardizzoni A
Lung Cancer; 2020 Nov; 149():5-9. PubMed ID: 32932213
[TBL] [Abstract][Full Text] [Related]
14. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
[TBL] [Abstract][Full Text] [Related]
15. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
[TBL] [Abstract][Full Text] [Related]
16. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Garrido P; Conde E; de Castro J; Gómez-Román JJ; Felip E; Pijuan L; Isla D; Sanz J; Paz-Ares L; López-Ríos F
Clin Transl Oncol; 2020 Jul; 22(7):989-1003. PubMed ID: 31598903
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.
Juan O; Popat S
Lung Cancer; 2017 Feb; 104():131-133. PubMed ID: 27863911
[No Abstract] [Full Text] [Related]
18. Clinical next-generation sequencing in patients with non-small cell lung cancer.
Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
[TBL] [Abstract][Full Text] [Related]
19. [Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
López-Ríos F; Paz-Ares L; Sanz J; Isla D; Pijuan L; Felip E; Gómez-Román JJ; de Castro J; Conde E; Garrido P
Rev Esp Patol; 2020; 53(3):167-181. PubMed ID: 32650968
[TBL] [Abstract][Full Text] [Related]
20. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]